Recombinant Mouse IL-31RA Fc Chimera Protein, CF

1 μg/lane of Recombinant Mouse IL‑31 RA was resolved with SDS-PAGE underreducing (R) and non-reducing (NR) conditions and visualized by silver staining,showing bands at 90-103 kDa and 180-210 kDa, respectively.

• Reactivity: Mu
• Applications: Binding Activity
• Format: Carrier-Free

Recombinant Mouse IL-31RA Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Mouse IL‑31 RA Fc Chimera is immobilized at 5 µg/mL (100 µL/well), Recombinant Mouse IL‑31 (Catalog # 3028-ML) binds with an ED₅₀ of 0.9-5.4 μg/mL.
• Source: Spodoptera frugiperda, Sf 21 (stably transfected)-derived mouse IL-31 RA protein
  

  Mouse IL-31RA (Val19-Ser503) Accession # AAM27959.1	DIEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: AAM27959.1
• N-terminal Sequence: Val19
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Binding Activity
• Theoretical MW: 82 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 90-103 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage:
  • 12 months from date of receipt, ≤ -20 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse IL-31RA Fc Chimera Protein, CF

• class I cytokine receptor
• CRL3
• CRL3Glmr
• Cytokine receptor-like 3
• GLMR
• GLM-R
• GLM-RMGC125346
• GP130 like receptor
• Gp130-like monocyte receptor
• Gp130-like receptor
• hGLM-R
• IL-31 RA
• IL-31 receptor subunit alpha
• IL-31R subunit alpha
• IL31RA
• IL-31RA
• IL-31RAGPLCRL
• IL-31R-alpha
• interleukin 31 receptor A
• interleukin-31 receptor subunit alpha
• PRO21384
• soluble type I cytokine receptor CRL3
• zcytoR17

Background

The interleukin-31 receptor A subunit (IL-31 RA), also known as gp130-Like Monocyte Receptor (GLM-R or GPL), is a ~100 kDa type I transmembrane glycoprotein that is classified as being a type I cytokine receptor (1, 2). A heterodimeric complex of IL-31 RA and the oncostatin M receptor (OSM R) functions as the signaling receptor for IL-31 (3). Both subunits are inducibly expressed throughout the myelomonocytic lineage and are up-regulated by interferon-gamma and bacterial lipopolysaccharides (1-3). IL-31 RA is also expressed on keratinocytes, dorsal root ganglia neurons, and variably on lung epithelial cells (3-6). The 716 amino acid (aa) mouse IL-31 RA contains an 18 aa signal sequence, a 481 aa extracellular domain (ECD), a 21 aa transmembrane domain and a 196 aa cytoplasmic domain. The ECD of mouse IL-31 RA shares 60% and 84% aa identity with human and rat IL-31 RA ECD, respectively. Mouse IL-31 receptors do not respond to human IL-31 (7). The ECD contains five fibronectin type III domains; the first two contain four conserved cysteine residues and a WSXWS motif common to type I cytokine receptors (2).  In both humans and transgenic mice, IL-31 from skin-homing Th2 cells may contribute to the pruritis (itching) associated with nonatopic dermatitis, especially in infected skin (3, 8, 9).

1. Ghilardi, N. et al. (2002) J. Biol. Chem. 277:16831.
2. Diveu, C. et al. (2003) J. Biol. Chem. 278:49850.
3. Dillon, S. R. et al. (2004) Nat. Immunol. 5:752.
4. Chattopadhyay, S. et al. (2007) J. Biol. Chem. 282:3014.
5. Perrigoue, J. G. et al. (2007) J. Exp. Med. 204:481.
6. Bando, T. et al. (2006) Neuroscience 142:1263.
7. Broxmeyer, H. E. et al. (2007) Exp. Hematol. 35:78.
8. Bilsborough, J. et al. (2006) J. Allergy Clin. Immunol. 117:418.
9. Sonkoly, E. et al. (2006) J. Allergy Clin. Immunol. 117:411.

Bioinformatics

• Uniprot:
  • AAM27959.1()